Daraxonrasib: Restoring Hope in Pancreatic Cancer Management

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult challenges in modern oncology. It is a condition characterised by aggressive tumour growth and a high mortality rate, with a five-year survival rate that persists below 13% (1). Because the disease is often asymptomatic in its early stages, the majority of patients are diagnosed only after the cancer has become metastatic and unresectable. While this mutation drives the disease, the RAS protein was long considered "undruggable" due to its smooth surface and lack of traditional binding pockets (1). However, the recent emergence of daraxonrasib (RMC-6236) represents a major shift in this narrative, offering a new therapeutic strategy for a patient population that has had very few targeted options (2).

Pancreatic cancer is the 10th most common cancer in the United States (3). While it represents only 3.3% of all new cancer cases, it accounts for a disproportionate 8.3% of all cancer-related deaths3. Pancreatic ductal adenocarcinoma (PDAC) is the most frequent form, making up over 90% of all cases. A defining feature of PDAC is the presence of activating RAS mutations, which drive more than 90% of these tumours. Among these, the G12D variant is the most common mutation seen in patients (1).

Demographic data reveal that incidence and mortality rates are notably higher in males than in females. Significant racial disparities also exist; the Black population experiences the highest incidence rates, followed by White and Asian or Pacific Islander populations (3). Although typically diagnosed in older adults, early-onset cases (patients under age 50) are a growing concern, now accounting for 5% to 12% of all new diagnoses (1).

Current Treatment Challenges

Patients with pancreatic cancer face a difficult journey marked by rapid disease progression and limited success with standard therapies. Current care usually involves intensive chemotherapy, such as FOLFIRINOX or a combination of gemcitabine and nab-paclitaxel. While these treatments offer some benefit, the median overall survival for patients with metastatic disease still typically remains under one year (1).

Beyond the clinical outlook, patients face heavy socioeconomic and personal burdens. The aggressive nature of the disease leads to a quick decline in physical functioning and quality of life. While researchers have developed inhibitors for specific mutations like KRAS G12C, these only apply to a tiny fraction of patients (4). The vast majority of patients possess different RAS variants, such as G12D or G12V, that traditional inhibitors cannot target (1). This has left a massive unmet need for a "pan-RAS" approach that can address the biological diversity of the disease (1,4).

Daraxonrasib by Revolution Medicines: Effective Relief for Persistent PDAC Symptoms

Developed by Revolution Medicines, daraxonrasib is a first-in-class oral drug for RAS-driven cancers. It uses a "molecular glue" mechanism to form a tri-complex between active RAS proteins and a natural protein called Cyclophilin A (CypA) (4). This shuts down the PI3K and MAPK signalling pathways that tell cancer cells to divide uncontrollably (4). As a pan-RAS(ON) inhibitor, it targets multiple mutations across KRAS, NRAS, and HRAS, as well as wild-type RAS variants (2).

Clinical Evidence from Phase 3 Trials

Daraxonrasib’s development has progressed rapidly following encouraging early results. In Phase 1/1b trials for previously treated RAS-mutant metastatic PDAC, the drug demonstrated significant anti-tumour activity, including objective responses and stable disease (2). These findings led to the pivotal RASolute 302 (NCT06625320) Phase 3 study (5). This global, multicenter trial compares daraxonrasib against standard chemotherapy for patients who have progressed after their first line of treatment. The study aims to enrol approximately 460 patients and to evaluate progression-free survival (PFS) and overall survival (OS) as primary endpoints. Early data suggest daraxonrasib provides meaningful benefits across various RAS mutations, representing a major milestone for second-line pancreatic cancer management (5).

FDA Approval

On August 26, 2026, the FDA gave its nod to Rasonque (daraxonrasib), a pioneering, once-daily oral RAS inhibitor created by Revolution Medicines, for adults suffering from metastatic pancreatic adenocarcinoma (7). This therapy is intended for individuals who have undergone at least one prior systemic treatment or who are ineligible for multiagent systemic therapy. By targeting various forms of the RAS protein, a remarkable driver of tumour proliferation, the medication focuses on the most prevalent type of pancreatic cancer. This remarkable approval, granted 6.5 months ahead of the expected timeline, is substantiated by a clinical trial involving 500 patients, where Rasonque notably enhanced median overall survival to 13.2 months, in contrast to 6.7 months for standard chemotherapy. Acknowledged for tackling a vital national public health concern, the medication underwent evaluation under the Commissioner's National Priority Voucher pilot initiative and received Breakthrough Therapy, Priority Review, and Orphan Drug classifications (7).

Safety and Tolerability Profile

Ensuring safety is a priority because inhibiting wild-type RAS can affect healthy cell signalling (4). To date, clinical studies show that daraxonrasib has a manageable safety profile. The most common side effects include low-grade rash (dermatological toxicity) and gastrointestinal issues, such as nausea or diarrhoea. To manage skin reactions, clinicians may prescribe topical corticosteroids or oral antibiotics as a preventive measure (5).

Preclinical research suggests that liver enzymes and transporters influence how the body processes the drug. For instance, the ABCB1 (P-gp) transporter restricts the drug's concentration in the brain. Despite these factors, clinical data indicate that side effects are generally tolerable (4). Patients are less likely to stop treatment due to these effects compared to those receiving intensive chemotherapy (5).

Clinical Dosage in Practice

In the Phase 3 trial, the recommended oral dose of daraxonrasib is 300 mg daily (4,5). This amount was selected to maximise suppression of the RAS pathway while ensuring the treatment remains tolerable for the patient (4). Clinicians should be aware that drug levels in the blood are influenced by the CYP3A4 enzyme and OATP1A/1B transporters, which makes monitoring for potential drug-drug interactions essential. While the medication effectively targets pancreatic tumours, its ability to enter the central nervous system is restricted by the blood-brain barrier. Finally, maintaining a consistent daily schedule is vital to achieve steady plasma levels and ensure the best therapeutic results (4).

Limitations and Future Perspectives

Although daraxonrasib is a major advancement, some patients eventually develop acquired resistance. This often happens through mutant KRAS amplification or the activation of alternative pathways like PI3K. Unlike some other KRAS inhibitors, daraxonrasib does not typically cause secondary mutations within the KRAS protein itself (2). To address these challenges, researchers are exploring combination therapies. Preclinical studies show that combining the drug with Tumour Treating Fields (TTFields) can significantly increase cancer cell death and inhibit migration (6). Additionally, using "boosters" to inhibit drug transporters may help the medication reach the brain more effectively to treat metastases (4). The ultimate goal is to transition from using daraxonrasib as a single agent to making it part of a personalised, multi-pronged treatment strategy.

Conclusion

Pancreatic cancer has long been defined by its resistance to treatment and poor prognosis. The ongoing study of daraxonrasib represents a significant advance in oncological care. By targeting the RAS pathway with a novel "molecular glue" mechanism, this drug addresses the fundamental driver found in more than 90% of PDAC cases.

For healthcare professionals, daraxonrasib offers a vital new tool that has shown encouraging efficacy and a manageable safety profile in trials. It holds the potential to improve survival and quality of life for patients with few remaining options. As the Phase 3 RASolute 302 trial progresses, the medical community remains hopeful that daraxonrasib will become a cornerstone of modern pancreatic cancer management.

---

About the Author

Dr. Manisha Dadlani is a Dental Surgeon and Medical Writer with 5+ years of clinical experience and formal training in medical writing. She combines clinical expertise with analytical thinking to develop evidence-based, insight-driven content that supports effective scientific communication across the healthcare and life sciences landscape.

---

References:

1. Scarlato E, Dusetti N, Melisi D. Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities. Cancer Treat Rev. 2026;145:103215. https://doi.org/10.1016/j.ctrv.2026.103123

   
   

2. Aronchik I, Kar S, Zhuang Y, et al. Resistance mechanisms to monotherapy RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC inform therapeutic combination strategies [abstract]. Mol Cancer Ther. 2025;24(10 Suppl):A081. https://doi.org/10.1158/1535-7163.TARG-25-A081

   
   

3. Ghimire C, Kenmoe J, Kandel P. The Effect of Advances in Pancreatic Cancer Treatment in Population Mortality: A Surveillance, Epidemiology, and End Results–based Study. Gastro Hep Advances, 2025; 5 https://www.ghadvances.org/article/S2772-5723(25)00126-8/fulltext 

   
   

4. Arguedas D, Bui V, Law T, Rijmers J, Tissier R, Beijnen JH, van Tellingen O, Lebre MC, Schinkel AH. Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolising enzymes on a first-in-class pan-RAS molecular glue. Pharmacol Res. 2026;223:108226. https://doi.org/10.1016/j.phrs.2026.108226

   
   

5. Brian M. Wolpin et al. Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 43, TPS4230-TPS4230(2025). DOI:10.1200/JCO.2025.43.16_suppl.TPS4230

   
   

6. Ishita Saha, Santanu Bhattacharya, Debabrata Mukhopadhyay, Hani M. Babiker; Abstract 4478: Synergistic antitumor activity of tumour-treating fields and multiselect-RAS (ON) inhibitor RMC-6236 in pancreatic ductal adenocarcinoma. Cancer Res 1 April 2026; 86 (7_Supplement): 4478. https://doi.org/10.1158/1538-7445.AM2026-4478

   
   

7.  FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma

   
   

---

Disclaimer

The matter published on this platform has been developed by independent medical writers from various healthcare backgrounds including members of MedWriters Alumni Network. Although great care has been taken in compiling and checking the information, the authors, Rxnews team and its partners or agents, and sponsors shall not be responsible or in any way liable for any errors, omissions, or inaccuracies in this blog article whether arising from negligence or otherwise, however or for any consequences arising therefrom. The inclusion and exclusion of any product do not mention that the publisher advocates or rejects its use generally or in any particular field. For any complaints or feedback please write to contact@crixus.co.in 

---